MARKET

DGNOF

DGNOF

Diagnos Inc
OTCMQB
0.240
-0.003
-1.07%
Opening 12:08 12/05 EST
OPEN
0.240
PREV CLOSE
0.243
HIGH
0.240
LOW
0.240
VOLUME
10.00K
TURNOVER
2.40K
52 WEEK HIGH
0.288
52 WEEK LOW
0.134
MARKET CAP
24.72M
P/E (TTM)
-6.9565
1D
5D
1M
3M
1Y
5Y
1D
Diagnos Inc. Upsizes Private Placement to $3.65 Million
Reuters · 11/25 14:06
DIAGNOS ANNOUNCES UPSIZE OF PREVIOUSLY ANNOUNCED BROKERED PRIVATE PLACEMENT TO $3.65M LED BY CENTURION ONE CAPITAL
Reuters · 11/25 14:00
Diagnos Inc. Releases Q2 2026 MD&A Report
Reuters · 11/20 16:57
Diagnos Inc. posts Q2 revenue of $15,159 with net loss of $1.01 million
Reuters · 11/20 16:57
Diagnos Inc. Launches $2 Million Private Placement Led by Centurion One Capital
Reuters · 11/10 21:36
DIAGNOS ANNOUNCES $2.0 MILLION BROKERED PRIVATE PLACEMENT LED BY CENTURION ONE CAPITAL
Reuters · 11/10 21:36
DIAGNOS STRENGTHENS GOVERNANCE AND LEADERSHIP WITH THE APPOINTMENT OF PHILIPPE COUILLARD AS CHAIRMAN OF THE BOARD OF DIRECTORS
Reuters · 10/30 13:00
DIAGNOS WELCOMES DR. PIERRE-LUC CHARLEBOIS TO ITS ADVISORY BOARD
Reuters · 10/27 13:00
More
About DGNOF
Diagnos Inc. is a Canadian company, which is engaged in the early detection of critical eye-related health problems using advanced technology based on Artificial Intelligence (AI). It markets Computer Assisted Retinal Analysis (CARA), a software platform which assists health specialists in the detection of certain retinopathy pathologies through the computerized analysis of retina images. CARA is an in-house-hosted Web-based application that integrates fundus cameras with an image processing engine over a secure Internet connection. The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), and pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularization). CARA is indicated for use by healthcare professionals in an adult general population in the context of a general eye-health exam.

Webull offers Diagnos Inc stock information, including OTCMQB: DGNOF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DGNOF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DGNOF stock methods without spending real money on the virtual paper trading platform.